Maedler Kathrin
Department of Medicine, Larry L. Hillblom Islet Research Center, University of California at Los Angeles, Los Angeles, CA 90095-7345, USA.
Diabetes Obes Metab. 2008 May;10(5):408-20. doi: 10.1111/j.1463-1326.2007.00718.x. Epub 2007 Apr 19.
The healthy beta-cell has an enormous capacity to adapt to conditions of higher insulin demand (e.g. in obesity, pregnancy, cortisol excess) to maintain normoglycaemia with an increase in its functional beta-cell mass. This compensates in 80-90% of individuals for insulin resistance. However, in 10-20% of individuals, the beta-cells are unable to match the demands of insulin resistance and insulin levels are relatively insufficient to maintain normal glycaemic control. This eventually leads to glucose intolerance and type 2 diabetes (T2DM). Accordingly, preservation of functional beta-cell mass has become central in the treatment of type 1 diabetes as well as T2DM. The purpose of this review is to summarize the recently described mechanisms of beta-cell death in T2DM and to postulate possible new targets for treatment.
健康的β细胞具有巨大的能力来适应更高胰岛素需求的情况(如肥胖、妊娠、皮质醇过多),通过增加功能性β细胞量来维持正常血糖。这在80%至90%的个体中可补偿胰岛素抵抗。然而,在10%至20%的个体中,β细胞无法满足胰岛素抵抗的需求,胰岛素水平相对不足以维持正常血糖控制。这最终导致葡萄糖不耐受和2型糖尿病(T2DM)。因此,保留功能性β细胞量已成为1型糖尿病和T2DM治疗的核心。本综述的目的是总结最近描述的T2DM中β细胞死亡的机制,并推测可能的新治疗靶点。